Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (121-130 of 724) with videos related to

Pageof 73
Sort By:
Seminars in Oncology|October 31, 2001
Docetaxel and exisulind in hormone-refractory prostate cancerC W Ryan, W M Stadler, N J Vogelzang
Journal of the National Cancer Institute|June 29, 2011
Randomized phase II trials: a long-term investment with promising returnsManish R Sharma, Walter M Stadler, Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?Walter M Stadler, Laura C Michaelis, Mark J Ratain
The Journal of Experimental Medicine|September 1, 1983
Factor-dependent in vitro growth of human normal bone marrow-derived basophil-like cellsK Tadokoro, B M Stadler, A L De Weck
BJU International|November 28, 2008
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancerMatthew I Milowsky, Walter M Stadler, Dean F Bajorin
European Journal of Immunology|May 1, 1994
Human anti-IgE antibodies by repertoire cloningM Vogel, S Miescher, C Biaggi, et al.
Journal of the National Cancer Institute|December 2, 1992
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicatorW M Stadler, J M Richards, N J Vogelzang
Oncogene|October 7, 2008
miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progressionM T Pickering, B M Stadler, T F Kowalik
Journal of the American Medical Informatics Association : JAMIA|November 22, 2011
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signaturesYves A Lussier, Walter M Stadler, James L Chen
Cancer|November 1, 1995
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinomaW M Stadler, M E Rybak, N J Vogelzang
Pageof 73

Showing results (121-130 of 724) with videos related to

Sort By:
Pageof 73
Seminars in Oncology|October 31, 2001
Docetaxel and exisulind in hormone-refractory prostate cancerC W Ryan, W M Stadler, N J Vogelzang
Journal of the National Cancer Institute|June 29, 2011
Randomized phase II trials: a long-term investment with promising returnsManish R Sharma, Walter M Stadler, Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?Walter M Stadler, Laura C Michaelis, Mark J Ratain
The Journal of Experimental Medicine|September 1, 1983
Factor-dependent in vitro growth of human normal bone marrow-derived basophil-like cellsK Tadokoro, B M Stadler, A L De Weck
BJU International|November 28, 2008
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancerMatthew I Milowsky, Walter M Stadler, Dean F Bajorin
European Journal of Immunology|May 1, 1994
Human anti-IgE antibodies by repertoire cloningM Vogel, S Miescher, C Biaggi, et al.
Journal of the National Cancer Institute|December 2, 1992
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicatorW M Stadler, J M Richards, N J Vogelzang
Oncogene|October 7, 2008
miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progressionM T Pickering, B M Stadler, T F Kowalik
Journal of the American Medical Informatics Association : JAMIA|November 22, 2011
Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signaturesYves A Lussier, Walter M Stadler, James L Chen
Cancer|November 1, 1995
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinomaW M Stadler, M E Rybak, N J Vogelzang
Pageof 73